Amid a wave of research into potential Covid-19 therapies, a new analysis warns that some trials are being run by universities and companies in Europe that either have no track record filing any trial results with a European database or have failed to do so in the past. As a result, there is a risk that past performance might undermine the ongoing search for safe and effective treatments, according to the advocacy group that conducted the analysis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,